|Articles|April 22, 2022
Nitrosamine Control: Understanding the New FDA and EMA Regulations
Author(s)SGS
This technical bulletin discusses major regulatory updates, introduced by the FDA and EMA, regarding nitrosamines and SGS proposed risk assessment method for compliance.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How FDA’s Bayesian Guidance Could Accelerate Adaptive Trial Design in Biopharmaceuticals
2
Beyond Transactional: Collaborative Partnerships for Rapid, Flexible Biologics Development
3
Generative AI and Adaptive Trials Shape Future Biotech Development
4
Executive Summary: From Molecule to Formulation: A Systematic Approach to Assess Biologics Developability
5